Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
EPITOPES
Document Type and Number:
WIPO Patent Application WO/2020/053304
Kind Code:
A3
Abstract:
The present invention relates to epitopes containing homocitrulline (Hcit) that can be used as targets for cancer immunotherapy. The homocitrullinated T cell epitope has (i) a predicted binding score to MHC class II or class I of < 30 using the online IEDB prediction program (http://www.iedb.org/) and (ii) at least 5 consecutive amino acids that form a spiral conformational structure. These modified peptides can be used as vaccines or as targets for T cell receptor (TCR) and adoptive T cell transfer therapies.

Inventors:
XUE WEI (GB)
COOK KATHERINE (GB)
DURRANT LINDA (GB)
BRENTVILLE VICTORIA (GB)
Application Number:
PCT/EP2019/074273
Publication Date:
June 18, 2020
Filing Date:
September 11, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SCANCELL LTD (GB)
International Classes:
C07K14/47; A61P35/00; C07K14/725; C12N9/88
Foreign References:
Other References:
ELENA B LUGLI ET AL: "Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, vol. 17, no. 1, 20 January 2015 (2015-01-20), pages 1 - 9, XP021214569, ISSN: 1478-6354, DOI: 10.1186/S13075-015-0520-X
CAROLINE OSPELT ET AL: "Carbamylation of vimentin is inducible by smoking and represents an independent autoantigen in rheumatoid arthritis", ANNALS OF THE RHEUMATIC DISEASES, vol. 76, no. 7, 9 February 2017 (2017-02-09), GB, pages 1176 - 1183, XP055647749, ISSN: 0003-4967, DOI: 10.1136/annrheumdis-2016-210059
MART├ŹNEZ GOITYBELL ET AL: "Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients", RHEUMATOLOGY INTERNATIONAL: CLINICAL AND EXPERIMENTAL INVESTIGATIONS, SPRINGER, DE, vol. 36, no. 6, 2 April 2016 (2016-04-02), pages 781 - 791, XP035873871, ISSN: 0172-8172, [retrieved on 20160402], DOI: 10.1007/S00296-016-3472-9
V. A. BRENTVILLE ET AL: "Citrullinated Vimentin Presented on MHC-II in Tumor Cells Is a Target for CD4+ T-Cell-Mediated Antitumor Immunity", CANCER RESEARCH, vol. 76, no. 3, 1 February 2016 (2016-02-01), US, pages 548 - 560, XP055524285, ISSN: 0008-5472, DOI: 10.1158/0008-5472.CAN-15-1085
VICTORIA A BRENTVILLE ET AL: "T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy", ONCOIMMUNOLOGY, vol. 8, no. 5, E1576490, 20 February 2019 (2019-02-20), pages 1 - 14, XP055690610, DOI: 10.1080/2162402X.2019.1576490
Attorney, Agent or Firm:
KILBURN & STRODE LLP et al. (GB)
Download PDF: